ARQT: Arcutis Biotherapeutics, Inc. Stock

by  •  • Comments Off on ARQT: Arcutis Biotherapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,484.71
Enterprise Value ($M) 1,554.47
Book Value ($M) 156.64
Book Value / Share 1.34
Price / Book 9.48
NCAV ($M) 143.01
NCAV / Share 1.22
Price / NCAV 10.38

Profitability (mra)
Return on Invested Capital (ROIC) -0.54
Return on Assets (ROA) -0.57
Return on Equity (ROE) -2.21

Liquidity (mrq)
Quick Ratio 2.38
Current Ratio 2.46

Balance Sheet (mrq) ($M)
Current Assets 423.72
Assets 437.35
Liabilities 280.71
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Point72 Asset Management, L.P. 0.20 -94.92
11-13 13G/A Rubric Capital Management LP 9.38 65.05
11-08 13G/A BlackRock, Inc. 7.70 0.00
11-06 13G/A Morgan Stanley 3.40 -34.46
03-06 13D/A Frazier Life Sciences VIII, L.P. 7.80 0.24
03-06 13G/A Jennison Associates Llc 10.80 33.78
02-14 13G/A Prudential Financial Inc 10.47 2.42
02-13 13G Vanguard Group Inc 5.19
02-13 13G/A Polar Capital Holdings Plc 6.67 -11.52
02-13 13G/A Suvretta Capital Management, Llc 9.99 -0.60
2024-01-23 13G/A State Street Corp 1.62 -58.55

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-07-24 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 368,406 1,697,522 21.70
2025-02-03 411,601 1,749,237 23.53
2025-01-31 291,321 1,329,506 21.91
2025-01-30 451,514 1,977,601 22.83

(click for more detail)

Similar Companies
ANAB – AnaptysBio, Inc. ANNX – Annexon, Inc.
APLS – Apellis Pharmaceuticals, Inc. ARVN – Arvinas, Inc.
ARWR – Arrowhead Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io